Takeaway

• The combination of nimotuzumab and gemcitabine prolonged survival (10.9 vs 8.5 months) In K-RAS wild-type locally advanced or metastatic pancreatic cancer (PC), compared to gemcitabine alone, particularly in patients without a surgical history.

Why this matters

• No effective treatments exist for advanced pancreatic adenocarcinoma.
• Nimotuzumab is a humanised...